20060101
A
61 K 38 16 A 20060101
A
61 K 39 12 A 20060101
C
07 K 14 08 A OA 1/2009/000341 20080410 US 60/922,732 20070410 THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
1430 Tulane Avenue US
US BAUSCH, Daniel, G.
425 Arabella Street US
BRANCO, Luis, M.
310 Prettyman Drive, No. 7310 US
CASHMAN, Kathleen, A.
603 Greysands Lane US
FAIR, Joseph, N.
1111 Weverton Rd., US
GARRY, Robert, F.
2114 Pine Street, US
GESKE, F., Jon
17490 E. 104th Place US
GUTTIERI, Mary, C.
3634 Islington Street US
ILLICK, Megan, M.
2445, Lyttonsville Road, No. 1108 US
KULAKOSKY, Peter, C.
510 Brockenbraugh Court US
MATSCHINER, Alexander
11840 Farmland Drive US
SAMPEY, Darryl, B.
171 South Columbus Avenue, US
WILSON, Russell, B.
146 Wisteria Lane US
SCP NICO HALLE & Co. LAW FIRM
ADRESSE A COMPLETER CM
Soluble and membrane-anchored forms of lassa virus subunit proteins. 20130329 015855 20280410 US PCT/US08/004622 20080410 IB WO/08/124176 20081016 20080410 20091009 20130329 BR Brevet PCT

The invention discloses compositions comprising soluble and membrane-anchored forms of Lassa virus (LASV) glycoprotein 1 (GP1), glycoprotein 2 (GP2), the glycoprotein precursor (GPC), the nucleocapsid protein (NP), and the nucleic acids encoding these proteins. This invention further relates to diagnostic and preventative methods using these compositions. Preventative methods include preparation of vaccines, as well as factors (e.g. small molecules) that inhibit LASV infectivity. Further, the invention relates to diagnostic and therapeutic antibodies including neutralizing antibodies for the prevention and treatment of infection by LASV and other arenaviruses.